Provectus Biopharmaceuticals, Inc.
OTC: PVCT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Edward V. Pershing
- Employees
- 6
- Headquarters
- Knoxville, United States
- IPO year
- 1997
- Market cap
- $28.7M
- Website
- https://www.provectusbio.com
Loading PVCT…
Loading profile data…Frequently asked questions about PVCT
What does Provectus Biopharmaceuticals, Inc. (PVCT) do?
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid...
Where does PVCT trade?
Provectus Biopharmaceuticals, Inc. (PVCT) trades on the Other OTC.
What sector is PVCT in?
Provectus Biopharmaceuticals, Inc. (PVCT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Provectus Biopharmaceuticals, Inc.?
Edward V. Pershing is the chief executive officer of Provectus Biopharmaceuticals, Inc. (PVCT).
Where is Provectus Biopharmaceuticals, Inc. headquartered?
Provectus Biopharmaceuticals, Inc. is headquartered in United States.
Does PVCT pay a dividend?
Provectus Biopharmaceuticals, Inc. (PVCT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PVCT go public?
Provectus Biopharmaceuticals, Inc. (PVCT) completed its initial public offering in 1997.